Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial disease

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Weiss, Dustin J ^a   Casale, George P ^a   Koutakis, Panagiotis ^a   Nella, Aikaterini A ^a   Swanson, Stanley A ^a   Zhu, Zhen ^a   Miserlis, Dimitrios ^a   Johanning, Jason M ^a,b   Pipinos, Iraklis I ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; CARBONYL DERIVATIVE;

ADULT; AORTOBIFEMORAL BYPASS; AORTOFEMORAL BYPASS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FEMOROPOPLITEAL BYPASS; FEMOROTIBIAL BYPASS; FLUORESCENCE MICROSCOPY; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEG AMPUTATION; LEG BLOOD FLOW; LEG ISCHEMIA; LEG REVASCULARIZATION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUANTITATIVE ANALYSIS;

ALDEHYDES; ANKLE BRACHIAL INDEX; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; OXIDATIVE STRESS; PERIPHERAL ARTERIAL DISEASE; PROTEIN CARBONYLATION;

EID: 84884521598     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-230     Document Type: Article

References (36)

1. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR, Greenland P, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003, 163:884-892. 10.1001/archinte.163.8.884, 12719196.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743. 10.1161/01.CIR.0000137913.26087.F0, 15262830.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45:S5-S67. 10.1016/j.jvs.2006.12.037, 17223489.
4. Pipinos II, Judge AR, Selsby JT, Zhu Z, Swanson SA, Nella AA, Dodd SL. The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. Vasc Endovascular Surg 2007, 41:481-489.
5. Pipinos II, Judge AR, Selsby JT, Zhu Z, Swanson SA, Nella AA, Dodd SL. The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type. Vasc Endovascular Surg 2008, 42:101-112. 10.1177/1538574408315995, 18390972.
6. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. Vasc Med 2000, 5:55-59.
7. Gardner AW, Killewich LA. Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. Vascular medicine 2001, 6:9-14.
8. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Prediction of claudication pain from clinical measurements obtained at rest. Med Sci Sports Exerc 1992, 24:163-170.
9. McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, Taylor L, Chan C, Celic L, Woolley C, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg 2004, 39:523-530. 10.1016/j.jvs.2003.08.038, 14981443.
10. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest 1968, 21:277-287. 10.3109/00365516809076995, 5708696.
11. Pipinos II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, Baxter BT, Lynch TG, Dodd SL. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic Biol Med 2006, 41:262-269. 10.1016/j.freeradbiomed.2006.04.003, 16814106.
12. Koutakis P, Johanning JM, Haynatzki GR, Myers SA, Stergiou N, Longo GM, Pipinos II. Abnormal joint powers before and after the onset of claudication symptoms. J Vasc Surg 2010, 52:340-347. 10.1016/j.jvs.2010.03.005, 2921796, 20670775.
13. Farinon AM, Marbini A, Gemignani F, Govoni E, Bragaglia MM, Sianesi M, Tedeschi F. Skeletal muscle and peripheral nerve changes caused by chronic arterial insufficiency-significance and clinical correlations-histological, histochemical and ultrastructural study. Clin Neuropathol 1984, 3:240-252.
14. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation 1993, 87:413-421. 10.1161/01.CIR.87.2.413, 8425290.
15. Pipinos I, Shepard AD, Anagnostopoulos PV, Katsamouris A, Boska MD. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. J Vasc Surg 2000, 31:944-952. 10.1067/mva.2000.106421, 10805885.
16. Bauer TA, Brass EP, Hiatt WR. Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg 2004, 40:488-493. 10.1016/j.jvs.2004.06.025, 15337878.
17. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol Heart Circ Physiol 2001, 280:H603-H609.
18. Marincola FM. In support of descriptive studies; relevance to translational research. J Transl Med 2007, 5:21. 10.1186/1479-5876-5-21, 1871566, 17474987.
19. Avery SV. Molecular targets of oxidative stress. Biochem J 2011, 434:201-210. 10.1042/BJ20101695, 21309749.
20. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 2006, 10:389-406. 10.1111/j.1582-4934.2006.tb00407.x, 16796807.
21. Uchida K. Protein-Bound 4-Hydroxy-2-Nonenal as a Marker of Oxidative Stress. J Clin Biochem Nutr 2005, 36:1-10.
22. Harris ME, Carney JM, Hua DH, Leedle RA. Detection of oxidation products in individual neurons by fluorescence microscopy. Exp Neurol 1994, 129:95-102. 10.1006/exnr.1994.1150, 7925846.
23. Hirao T, Takahashi M. Carbonylation of cornified envelopes in the stratum corneum. FEBS Lett 2005, 579:6870-6874. 10.1016/j.febslet.2005.11.032, 16336969.
24. Huang D, Casale GP, Tian J, Lele SM, Pisarev VM, Simpson MA, Hemstreet GP. Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer 2009, 126:315-327.
25. Huang D, Casale GP, Tian J, Wehbi NK, Abrahams NA, Kaleem Z, Smith LM, Johansson SL, Elkahwaji JE, Hemstreet GP. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens. Cancer Epidemiol Biomarkers Prev 2007, 16:1371-1381. 10.1158/1055-9965.EPI-06-0718, 17623804.
26. LoPachin RM, Gavin T, Petersen DR, Barber DS. Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. Chem Res Toxicol 2009, 22:1499-1508. 10.1021/tx900147g, 19610654.
27. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004, 37:937-945. 10.1016/j.freeradbiomed.2004.06.012, 15336309.
28. Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004, 1033:92-98. 10.1196/annals.1320.008, 15591006.
29. Hickman P, Harrison DK, Hill A, McLaren M, Tamei H, McCollum PT, Belch JJ. Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. Adv Exp Med Biol 1994, 361:565-570. 10.1007/978-1-4615-1875-4_96, 7597984.
30. Silvestro A, Scopacasa F, Oliva G, de Cristofaro T, Iuliano L, Brevetti G. Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication. Atherosclerosis 2002, 165:277-283. 10.1016/S0021-9150(02)00235-6, 12417278.
31. Pipinos II, Swanson SA, Zhu Z, Nella AA, Weiss DJ, Gutti TL, McComb RD, Baxter BT, Lynch TG, Casale GP. Chronically ischemic mouse skeletal muscle exhibits myopathy in association with mitochondrial dysfunction and oxidative damage. Am J Physiol Regul Integr Comp Physiol 2008, 295:R290-R296. 10.1152/ajpregu.90374.2008, 2494805, 18480238.
32. Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 2007, 27:817-868. 10.1002/med.20073, 17044003.
33. Hashimoto M, Sibata T, Wasada H, Toyokuni S, Uchida K. Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct. J Biol Chem 2003, 278:5044-5051. 10.1074/jbc.M210129200, 12473681.
34. Makris KI, Nella AA, Zhu Z, Swanson SA, Casale GP, Gutti TL, Judge AR, Pipinos II. Mitochondriopathy of peripheral arterial disease. Vascular 2007, 15:336-343. 10.2310/6670.2007.00054, 18053417.
35. Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation 2011, 123:87-97. 10.1161/CIRCULATIONAHA.109.881888, 3061490, 21200015.
36. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol 1996, 81:780-788.